Conexeu Sciences expands board to nine after Nasdaq listing

Conexeu Sciences Inc. (NASDAQ: CNXU), a preclinical-stage regenerative-tissue company that began trading on the Nasdaq in May 2026, announced five leadership appointments on June 15, 2026, expanding its board from six to nine directors.

The three new directors are Ana Bastiani-Posner, April Burke, and Andrew Costa. Bastiani-Posner, named chair of the Compensation Committee, currently serves as Executive Vice President and CFO of Kyowa Kirin North America and has previously held senior roles at Allergan, Schering-Plough, and Novartis. Burke, joining the Audit and Compensation Committees, is EVP and CFO of Lucid Hearing. Costa, named chair of the Audit Committee, is Co-Managing Partner of RX3 Growth Partners and previously held investment-banking roles at Morgan Stanley and J.P. Morgan.

Co-founder and director David Bogart was elevated to Chief Commercial Officer. The company states he has advised on more than $75 million in capital formation and helped shape its intellectual property and regulatory strategy. Melinda Farina, founder of Integrated Aesthetics Consulting and Beauty Brokers Inc., joined the advisory board.

"Conexeu is entering an exciting new phase of growth, and it is important that our leadership team reflects the breadth of expertise needed to support both our scientific vision and business strategy," said CEO Miles Harrison.

Conexeu's lead device candidate, Ten-Minute Tissue, is a thermosensitive extracellular matrix platform, branded CXU, that remains fluid at room temperature and transitions to a gel scaffold at body temperature. The company is targeting an FDA 510(k) submission for an initial wound-care indication in early 2027. The CXU platform has not been reviewed or cleared by the FDA, and its safety and effectiveness have not been established.

The company also has a preclinical breast reconstruction program, B.R.E.A.S.T., in development with the Wake Forest Institute for Regenerative Medicine. This content is based on a press release distributed on behalf of Conexeu Sciences, for which the distributor has received compensation, constituting a conflict of interest.

You May Also Be Interested In

• HCW Biologics requests FDA meeting for T-cell engager HCW11-018b
• Hamilton Lane adds Michael Schmertzler to its board of directors
• iMDx kidney transplant test featured in Lancet study, gets Medicare nod